Intellia Therapeutics

CRISPR gene editing
#Advanced Therapies #FDA #Gene therapy #Intellia Therapeutics #Phase III trial

Regulator lifts clinical hold on Intellia’s gene therapy trials

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase III clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).  The clinical holds on the INDs for MAGNITUDE and MAGNITUDE-2 were imposed… Read More

#News #Regulatory #Trending News

CRISPR gene editing
#Cardiovascular disease #Gene editing #Gene therapy #Intellia Therapeutics #Phase III trial

Intellia pauses gene therapy trial due to liver injury

Intellia Therapeutics announced it has temporarily paused its MAGNITUDE and MAGNITUDE-2 Phase III clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively.  The action follows a report of Grade 4 liver transaminases and increased total bilirubin in a patient who… Read More

#Editor's Choice #News

CRISPR Cas9
#CRISPR #Genetics / genomics #Intellia Therapeutics #Phase I trial #Rare disease

Evidence supports redosing with an in vivo CRISPR-based therapy

Intellia Therapeutics has shared the first-ever clinical data demonstrating the potential for redosing with an investigational in vivo CRISPR-based therapy. The data from the ongoing Phase I study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at the Peripheral Nerve Society Annual Meeting. Read More

#News

#Clinical trial #CRISPR #FDA #Gene editing #Gene therapy #In vivo #Intellia Therapeutics

FDA clears in vivo gene editing therapy for trials in US

The US Food and Drug Administration (FDA) has cleared Intellia Therapeutics’ Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).  Intellia is a clinical-stage genome editing company focused on developing potentially curative therapies using CRISPR-based technologies.   The decision will enable the company to include the… Read More

#News #Regulatory #Trending News